XML 47 R23.htm IDEA: XBRL DOCUMENT v3.7.0.1

Note 4 - Investment in Wanchun Pharma (Tables)

12 Months Ended

Dec. 31, 2016

Notes Tables

Schedule of Business Acquisitions, by Acquisition [Table Text Block]

			$
Acquisition cost			2,400
Less: negative equity investment in Wanchun Pharma			(239	)
Less: net assets of Wanchun Pharma (including cash of $1,256)			(1,347	)
Excess cost allocated to patent of Plinabulin and charged to expenses			814

X

- Definition

Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463

+ Details

Name:	us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_TableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration